To follow our news, sign up for NeoNEWS, our email newsletter.
June 2, 2017
June 2, 2017 NeoGenomics Announces Expansion of Immuno-Oncology Profiling Tests
May 15, 2017 NeoGenomics Reports that its NeoLAB® Liquid Biopsy Prostate Test is More Accurate than Conventional Biopsies in Predicting High Grade Prostate Cancer
April 26, 2017 NeoGenomics Reports 15% Volume Growth and 10% Reduction in Average Cost per Test in the First Quarter of 2017
March 13, 2017 NeoGenomics and Definiens Enter Into Agreement to Develop Novel Assays for Clinical Trials & Clinical Testing
February 22, 2017 NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016
February 8, 2017 NeoGenomics Schedules its Q4 and Full Year 2016 Earnings Release for February 22, 2017
December 22, 2016 NeoGenomics Closes $150 Million Senior Credit Facility
October 26, 2016 NeoGenomics Reports 142% Revenue Growth to $60.8 Million and a Record $9.6 Million in Cash Flow from Operations in the Third Quarter of 2016
October 11, 2016 NeoGenomics Schedules its Q3 2016 Earnings Release for October 26, 2016
Jul 26, 2016 NeoGenomics Reports 159% Revenue Growth to $63.1 Million and Strong Gains in Profitability in the Second Quarter of 2016
Jul 5, 2016 NeoGenomics Schedules its Q2 2016 Earnings Release for July 26, 2016
Apr 27, 2016 NeoGenomics Reports 159% Revenue growth to $59.7 Million and 442% Adjusted EBITDA increase to $8.2 Million, Driven by Clarient acquisition and Strong Volume Gains
Apr 11, 2016 NeoGenomics Schedules its Q1 2016 Earnings Release for April 27, 2016
Mar 1, 2016 NeoGenomics Reports Record Revenue of $27.2 Million and Record Adjusted EBITDA of $2.9 Million in Fourth Quarter, Driven by Strong Volume Gains
Jan 26, 2016 NeoGenomics Schedules its Q4 2015 and full year 2015 Earnings Release for March 1, 2016
Dec 30, 2015 NeoGenomics Completes Acquisition of Clarient, Inc.
Dec 8, 2015 NeoGenomics Launches new Liquid Biopsy Tests for Monitoring Solid Tumors and Predicting Resistance to BTK Inhibitors
Oct 29, 2015 NeoGenomics Reports Revenue of $25.1 Million and Record Adjusted EBITDA of $2.8 Million Driven by a 25% Increase in Test Volume in the Third Quarter of 2015
Oct 28, 2015 NeoGenomics Amends Strategic Alliance Agreement with Covance Central Laboratory Services
Oct 21, 2015 NeoGenomics signs Definitive Agreement to acquire Clarient, Inc.
Oct 12, 2015 NeoGenomics Schedules its Q3 2015 Earnings Release for October 29, 2015
Sep 23, 2015 NeoGenomics Launches new NeoSITE™ Cervical FISH Assay for Evaluation of Abnormal Pap Tests
Sep 2, 2015 NeoGenomics Enters into National Agreement with Premier, Inc. to Offer Cancer Genetics Testing Services to 3,600 Hospitals